Bispecific antibodies for the treatment of breast cancer. (3rd August 2022)

• Record Type: Journal Article
• Authors: Dillon, Patrick M.; Tushir-Singh, Jogender; Lum, Lawrence G.
• Is Part Of: Expert opinion on biological therapy. Volume 22:Number 8(2022)
• Page Start: 1017
• Page End: 1027
• Publication Date: 2022-08-03
• Subjects: Bispecific antibody -- breast cancer -- immunotherapy -- clinical trials -- cellular therapy; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2021.1922665
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: There are more than two dozen bispecific antibodies (BsAbs) in development with a variety of designs which are relevant to breast cancer. The field of BsAbs for breast cancer includes agents that co-direct immune recognition of the cancer cell, target unique cancer antigens, and target the microenvironment. BsAbs are being developed for use as antibody-drug conjugates and as homing signals for engineered T-cells. Areas covered: This review covers potential targets for bispecific antibodies, agents in pre-clinical development, agents in clinical trials, combinatorial therapies, and future directions. Expert opinion: There is no BsAb approval expected for breast cancer in the near term, but late-stage trials are underway. Future BsAb roles in breast cancer are possible given unmet needs in estrogen receptor+ disease, residual disease, and de-escalating chemotherapy use. The HER2+ space shows hints of success for BsAbs, but is already crowded. Areas of unmet need still exist.